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Summary
Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being 
genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we 
aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at 
death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72.
Methods In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and 
disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in 
the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used 
mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups 
and individual mutations. We also assessed correlations between the age at onset and at death of each individual and 
the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, 
we used mixed effects models to investigate the extent to which variability in age at onset and at death could be 
accounted for by family membership and the specific mutation carried.
Findings Data were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 
1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 
67 different mutations). Mean age at symptom onset and at death was 49·5 years (SD 10·0; onset) and 58·5 years 
(11·3; death) in the MAPT group, 58·2 years (9·8; onset) and 65·3 years (10·9; death) in the C9orf72 group, and 
61·3 years (8·8; onset) and 68·8 years (9·7; death) in the GRN group. Mean disease duration was 6·4 years 
(SD 4·9) in the C9orf72 group, 7·1 years (3·9) in the GRN group, and 9·3 years (6·4) in the MAPT group. 
Individual age at onset and at death was significantly correlated with both parental age at onset and at death and 
with mean family age at onset and at death in all three groups, with a stronger correlation observed in the MAPT 
group (r=0·45 between individual and parental age at onset, r=0·63 between individual and mean family age at 
onset, r=0·58 between individual and parental age at death, and r=0·69 between individual and mean family age 
at death) than in either the C9orf72 group (r=0·32 individual and parental age at onset, r=0·36 individual and 
mean family age at onset, r=0·38 individual and parental age at death, and r=0·40 individual and mean family age 
at death) or the GRN group (r=0·22 individual and parental age at onset, r=0·18 individual and mean family age at 
onset, r=0·22 individual and parental age at death, and r=0·32 individual and mean family age at death). Modelling 
showed that the variability in age at onset and at death in the MAPT group was explained partly by the specific 
mutation (48%, 95% CI 35–62, for age at onset; 61%, 47–73, for age at death), and even more by family membership 
(66%, 56–75, for age at onset; 74%, 65–82, for age at death). In the GRN group, only 2% (0–10) of the variability of 
age at onset and 9% (3–21) of that of age of death was explained by the specific mutation, whereas 14% (9–22) 
of the variability of age at onset and 20% (12–30) of that of age at death was explained by family membership. In 
the C9orf72 group, family membership explained 17% (11–26) of the variability of age at onset and 19% (12–29) of 
that of age at death.
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Interpretation Our study showed that age at symptom onset and at death of people with genetic frontotemporal 
dementia is influenced by genetic group and, particularly for MAPT mutations, by the specific mutation carried 
and by family membership. Although estimation of age at onset will be an important factor in future pre-
symptomatic therapeutic trials for all three genetic groups, our study suggests that data from other members of 
the family will be particularly helpful only for individuals with MAPT mutations. Further work in identifying 
both genetic and environmental factors that modify phenotype in all groups will be important to improve such 
estimates.
Funding UK Medical Research Council, National Institute for Health Research, and Alzheimer’s Society.
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Introduction
Frontotemporal dementia is a genetically and patho­
logically hetero geneous neurodegenerative disease.1 The 
most common clinical subtypes of this disease are 
behavioural variant frontotemporal dementia, present­
ing with changes in personality and executive dys­
function, and primary progress ive aphasia, in which 
individuals develop impair ment of language processing. 
Three forms of primary progressive aphasia have been 
described: seman tic, non­fluent or agrammatic, and 
logopenic; how ever, up to 20% of people do not fit the 
criteria for any of these variants and are categorised as 
having prim ary progressive aphasia not other wise speci­
fied.2 Both behavioural variant fronto temporal dementia 
and primary progressive aphasia over lap with amyo­
trophic lateral sclerosis and with the atyp ical parkinson­
ian syndromes corticobasal syndrome and progressive 
supranuclear palsy.1 
Research in context
Evidence before this study
We searched PubMed for articles on genetic frontotemporal 
dementia with no language restrictions from database 
inception up to July 1, 2017, using the following terms: 
“frontotemporal dementia AND genetics”, “progranulin OR 
GRN”, “tau OR MAPT”, and “chromosome 9 open reading frame 
72 OR C9orf72”, focusing on studies that reported age at 
symptom onset, age at death or disease duration of individuals 
with symptoms. No studies were found that had systematically 
investigated age at symptom onset, age at death, or disease 
duration across all the different genetic groups and the different 
mutations found within the groups. However, evidence from 
cohort studies and individual case series suggested that the age 
at symptom onset, age at death, and disease duration were 
highly variable across the genes implicated in frontotemporal 
dementia. Age-related penetrance was described in individuals 
with GRN and C9orf72 mutations, with MAPT mutations usually 
being fully penetrant. We found a generational difference in age 
at symptom onset, with an earlier onset in later generations 
occurring in individuals with GRN or C9orf72 mutations. 
Phenotypic differences in age at symptom onset have not been 
studied in detail yet, but one study showed a shorter disease 
duration in individuals with a diagnosis of amyotrophic lateral 
sclerosis in the C9orf72 group compared with those with other 
diagnoses, and another study showed an earlier age at 
symptom onset in this group compared with that of 
other diagnoses.
Added value of this study
To our knowledge, this is the largest international study to date 
investigating individual age at symptom onset, age at death, 
and disease duration in patients with genetic frontotemporal 
dementia, across all the three main genetic groups (C9orf72, 
GRN, and MAPT), and all known mutations within the GRN and 
MAPT groups. Our study provides important evidence about 
the factors underlying age at symptom onset, age at death, and 
disease duration in the different groups. We showed that only in 
the MAPT mutation group were age at symptom onset and at 
death highly correlated with both parental and mean family 
ages at symptom onset and at death, with variability in these 
ages explained partly by the specific mutation and more so by 
family membership. Such correlations were weaker in the other 
two groups, with the variability in age at symptom onset 
and age at death for individuals with GRN mutations and 
C9orf72 expansions not accounted for particularly by family 
membership or, for individuals with GRN mutations, by the 
specific mutation. This is the first time that such key differences 
between genetic frontotemporal dementia groups have 
been shown.
Implications of all the available evidence
Optimal therapeutic trial design will be important in genetic 
frontotemporal dementia, and particularly because many trials 
will aim to include presymptomatic individuals who are 
expected to be in proximity to symptom onset. Our study 
suggests that in individuals with MAPT mutations data from 
other family members will be particularly helpful in estimating 
time from symptom onset. Further work is needed to 
understand the variability in the other genetic groups, and 
other proximity markers, either individually or in combination, 
are likely to be required to refine the estimation of time to 
symptom onset in individuals with GRN or C9orf72 mutations. 
In the meantime, the available data will provide clinicians and 
family members with a better understanding of the individual 
risk of probable symptom onset and time to death in each 
genetic group and within individual mutations.
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About a third of frontotemporal dementia cases are 
genetic,3 with mutations in multiple genes shown to be 
causative of this disease. However, most of the heritability 
of frontotemporal dementia is accounted for by muta­
tions in three genes: progranulin (GRN), microtubule­
associated protein tau (MAPT), and chromo some 9 open 
reading frame 72 (C9orf72; also known as C9orf72­SMCR8 
complex subunit). Although much has been learned over 
the past decade about the clinical features of these 
genetic forms of frontotemporal demen tia, most studies 
explor ing age at symptom onset and disease duration 
have been small and geographic ally restricted.4–6 In 
particular, although indivi dual case series have suggested 
that such phenotypic characteristics can be quite variable, 
no studies have syste matically investi gated these factors 
across all the differ ent genetic groups and the different 
mutations found within these groups.
Therefore, in this large international study, we aimed to 
analyse phenotypic characteristics of the main three forms 
of genetic frontotemporal dementia, including ages at 
symptom onset and death and disease duration, as well as 
examining the effect of mutation type and family member­
ship on these factors.
Methods
Study design and participants
In this international retrospective cohort study, we collec­
ted data from centres that are part of the Frontotemporal 
Dementia Prevention Initiative (FPI) and through a litera­
ture review of publications. The FPI is a group connecting 
natural history cohort studies of gen etic frontotemp­
oral dementia: the Genetic Frontotemporal Dementia 
Initiative (GENFI),7 Advancing Research and Treat ment 
for Frontotemporal Lobar Degeneration (ARTFL), 
Longitudinal Evaluation of Familial Frontotemporal 
Dementia Subjects (LEFFTDS), and the Dominantly 
Inherited Non­Alzheimer’s Dementias (DINAD) studies. 
These research studies include most of the centres 
investigat ing genetic frontotemporal dementia in Europe 
and eastern Canada (GENFI), USA and western Canada 
(ARTFL and LEFFTDS), and Australia (DINAD). In total, 
33 centres across the world (12 countries; appendix p 20) 
provided participant data for our study. We included all 
known pathogenic mutations in the GRN, MAPT, and 
C9orf72 genes in our study. Families with intermediate 
length expansions of C9orf72 were not included in the 
study. All mutations were reviewed by two geneticists 
(RG and JB) to examine pathogenicity and were only inclu­
ded if both agreed on their probable patho genic nature 
(full inclusion and exclusion criteria are in the appendix, p 
2). Local ethics committees at each of the sites approved 
the study and data from participants was provided through 
informed written consent.
Procedures 
Participant data collected from FPI centres included 
genetic group, individual mutation (for participants with 
mutations in GRN and MAPT), sex, clinical phenotype, 
age at symptom onset (defined by the onset of progressi­
ve behavioural, cognitive, or motor symptoms reported 
either by an informant [usually a family member] or, for 
non­behavioural symptoms, by the patient them selves), 
age at death, and relationship to other affected family 
members.
For the literature review, we assessed publications cited 
in the Alzheimer Disease & Frontotemporal Dementia 
Mutation database, and supplemented this by a detailed 
search of PubMed (done between Jan 1, 2015, and 
July 1, 2017) for other publications with data for age at 
symp tom onset, age at death, or disease dura tion in 
people with genetic frontotemporal dementia: this identi­
fied 308 journal articles. To avoid potential double rep­
orting, centres were asked to provide a list of publications 
relevant to their dataset. These lists were then manually 
examined for possible duplicates, which were removed 
when identified.
Statistical analysis
We grouped participants into a GRN, MAPT, or C9orf72 
group according to the mutation present. We calculated 
the numbers and percentages of participants within 
each genetic group by geo graphic location and clinical 
phenotype. We used a χ² test to compare sex distribu­
tion in each of the genetic groups. We calculated means 
and SDs for age at symptom onset, age at death, and 
disease duration in each genetic group and in the most 
common muta tions in the MAPT and GRN groups 
(defined as those identified in the greatest number of 
individuals in the study). We used mixed effects models 
to examine differ ences in age at symp tom onset, age at 
death, and disease duration bet ween genetic groups 
(GRN, MAPT, and C9orf72), between the most common 
mutations in the GRN and MAPT groups, between an 
earlier (first) and later (second) generation of family 
members in all genetic groups, between men and 
women within each genetic group, and between the 
main clinical pheno types within each genetic group. 
Analyses accounted for relatedness by including family 
membership as a random effect. We calculated Pearson 
correlation coeffici ents to explore the relationship 
between an indi vidual’s age at symp tom onset (or 
death) and the age at symp tom onset (or death) of 
their affected parent and the association between an 
individual’s age at symptom onset (or death) and the 
average age at symptom onset (or death) of other 
members of the same family. Lastly, we also used mixed 
effects models to explore the extent to which variability 
in age at symptom onset and at death were explained 
by family membership (explor ing variability both 
within and between families) and the specific muta tion 
carried (in GRN and MAPT groups). Detailed statis­
tical methods are shown in the app endix (pp 15–19). 
All statistical analyses were done with Stata (v.14 
or later).
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Results 
Our combined dataset comprised 3403 symp to matic indi­
viduals from 1492 families who had data available for one 
or more of age at symptom onset, age at death, disease 
duration, and clinical phenotype (table 1): 1433 individuals 
with C9orf72 expansions (from 755 families), 1179 with 
GRN mutations (483 families), and 791 with MAPT muta­
tions (254 families).
In total, 130 GRN mutations and 67 MAPT mutations 
were identified and all were included in the study 
(appendix pp 5–10). We found 78 GRN and 45 MAPT 
pathogenic mutations through the Alzheimer Disease & 
Frontotemporal Dementia Mutation database, 35 GRN 
and 18 MAPT variants, which were not included in the 
database, through a PubMed search, and the FPI centres 
provided data on an additional 17 GRN and four MAPT 
variants not previously described in the literature (appen­
dix p 2). The most common GRN mutations were Thr272fs 
(rs63749877; 201 individuals, 95 families), Arg493X 
(rs63751294; 55 individuals, 22 families), IVS7–1G→A 
(50 individuals, 18 families), Cys31fs (rs63751057, 47 indi ­
viduals, 10 families), Gly35fs (rs63751073, 42 individuals, 
10 families), and Ala9Asp (rs63751243, 37 individuals, 
four families). The most common MAPT mutations 
were Pro301Leu (rs63751273, 234 individuals, 59 families), 
IVS10 + 16C→T (rs63751011; 149 individuals, 48 families), 
Arg406Trp (rs63750424, 67 individuals, nine families), and 
Asn279Lys (rs63750756, 44 individuals, 17 families).
Overall, the most prevalent genetic group was that 
comprising individuals carrying a C9orf72 expansion 
(1433 [42·1%] of 3403 individuals), followed by individuals 
with GRN mutations (1179 [34·6%]), with individuals 
carrying MAPT mutations comprising the least common 
group (791 [23·2%]; figure 1). However, we observed 
geographical variability in the distribution of these muta­
tions, with a different spread of frequencies among the 
three genetic groups in some countries and regions: indi­
viduals with GRN mutations were more common than 
those of other groups in Italy (289 [66%] of 438 individuals) 
and, to a lesser extent, in Spain (76 [49%] of 155); whereas 
individuals with MAPT muta tions were found more 
frequently in the Netherlands (81 [40%] of 204) and 
the US west coast (71 [47%] of 150; appendix pp 20–23).
Although behavioural variant frontotemporal dementia 
was the most common diagnosis in each genetic group, 
we observed phenotypic variability across the different 
mutations (table 2; appendix pp 24–32). Both C9orf72 and 
MAPT groups contained approximately equal numbers of 
men and women (table 1, appendix pp 33–34). However, 
the GRN group had a significant overrepresentation of 
women compared with both the C9orf72 group and the 
MAPT group.
The mean age at symptom onset was lowest for the 
MAPT group, which was significantly lower than those 
of the GRN and C9orf72 groups (p<0·0001 for each 
GRN
(n=1179)
MAPT
(n=791)
C9orf72
(n=1433)
Difference 
MAPT vs GRN
Difference 
C9orf72 vs GRN
Difference 
C9orf72 vs MAPT
p value  
MAPT vs GRN
p value 
C9orf72 vs GRN
p value  
C9orf72 vs MAPT
Sex (n [%]) ·· ·· ·· ·· ·· ·· 0·0015 <0·0001 0·18
Men 490 (41·6%) 386 (48·8%) 742 (51·8%) ·· ·· ·· ·· ·· ··
Women 689 (58·4%) 405 (51·2%) 691 (48·2%) ·· ·· ·· ·· ·· ··
Number of families 483 254 755 ·· ·· ·· ·· ·· ··
Age at symptom onset 
(years)
·· ·· ·· –11·8 
(–13·0 to –10·6)
–2·8 
(–3·8 to –1·9)
9·0  
(7·8 to 10·1)
<0·0001 <0·0001 <0·0001
Mean (SD; n) 61·3 
(8·8; n=967)
49·5 
(10·0; n=609)
58·2 
(9·8; n=1076)
·· ·· ·· ·· ·· ··
Range 25–90 17–82 20–91 ·· ·· ·· ·· ·· ··
Age at death (years) ·· ·· ·· –10·7 
(–12·3 to –9·1)
–3·5 
(–4·9 to –2·2)
7·2  
(5·7 to 8·6)
<0·0001 <0·0001 <0·0001
Mean (SD; n) 68·8 
(9·7; n=656)
58·5 
(11·3; n=485)
65·3 
(10·9; n=839)
·· ·· ·· ·· ·· ··
Range 42–98 24–93 26–97 ·· ·· ·· ·· ·· ··
Disease duration (years) ·· ·· ·· 0·18 
(0·08 to 0·29)
–0·26 
(–0·35 to –0·17)
–0·44 
(–0·54 to –0·34)
0·0005 <0·0001 <0·0001
Mean (SD; n) 7·1 
(3·9; n=548)
9·3 
(6·4; n=394)
6·4 
(4·9; n=618)
·· ·· ·· ·· ·· ··
Range 0–27 0–45 0–36 ·· ·· ·· ·· ·· ··
For age at symptom onset, age at death, and disease duration, differences are adjusted mean differences (natural log values for disease duration) with 95% CIs. For sex differences, p values calculated with a 
χ² test. For age at symptom onset, age at death, and disease duration, p values calculated with mixed effects models. 
Table 1: Patient demographics and age at symptom onset, age at death, and disease duration in each of the three genetic groups
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comparison). The C9orf72 group had the second lowest 
age, which was significantly lower than that of the GRN 
group (p<0·0001; table 1, appendix pp 35–36). However, we 
observed a wide range of age at symptom onset within 
each of the genetic groups, from the 20s to the 90s in the 
GRN and C9orf72 groups and from age 17 years to the 80s 
in the MAPT group (figure 2, appendix pp 36). Cumulative 
probability curves for age at symptom onset in each of the 
genetic groups are shown in figure 3A (appendix p 39).
We also observed a wide range of age at symptom onset 
among GRN and MAPT mutations (appendix pp 6–10). 
We plotted cumulative probability curves for age at symp­
tom onset for the most common GRN (figure 3B) and 
MAPT (figure 3C) mutations (appendix p 39). These curves 
largely overlapped for the GRN mutations, without any 
signi ficant difference between groups. By contrast, we 
observed a significant difference between MAPT muta­
tions, with the Asn279Lys mutation group having a lower 
age at symptom onset (mean 43·8 years, SD 6·7) than that 
of the other groups (p≤0·0026 for all comparisons; 
appendix p 40). The generational analysis showed a 
significantly lower age at symptom onset in the second 
(later) generation than the first (earlier generation) in 
all three groups: mean age was 65·5 years (SD 9·1) in 
GRN first generation and 60·7 years (8·9) in GRN sec­
ond genera tion (p<0·0001); 62·3 years (10·9) in C9orf72 
first generation and 56·7 years (11·0) in C9orf72 second 
generation (p<0·0001); and 51·4 years (9·5) in MAPT 
first genera tion and 49·6 years (10·0) in MAPT second 
generation (p=0·011; appendix pp 41–43).
We found no significant differences in age at symptom 
onset between men and women in the MAPT group 
Figure 1: Frequency of each of the three genetic groups by geographic location
Countries with data included in the study are shown in dark blue (appendix p 20). Individual centres are shown as red dots on the map. Pie charts show relative frequency of each of the three genetic 
groups within a geographical area, with the number in the centre representing the number of cases included within that area.
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(appendix p 44). However, in the GRN group, women were 
significantly older at symptom onset (61·8 years, SD 9·2) 
than men (60·5 years, 8·3; p=0·019), with the same 
observed in the C9orf72 group (58·9 years, SD 9·6, in 
women, compared with 57·7 years, 10·0, in men [p=0·041]).
In the C9orf72 group, we found no significant differences 
in mean age at symptom onset between individuals with 
different clinical phenotypes, except for those with a 
diagnosis of Alzheimer’s disease (appendix pp 45–46). 
These individuals were significantly older at symptom 
onset than individuals with other phenotypes (mean 
65·1 years, SD 10·6; p<0·0001 for all comparisons except 
for that with primary progressive aphasia [p=0·010]). 
Similarly, we found no significant differences in age at 
symptom onset between individuals with different clinical 
phenotypes in the GRN group, except for those with a 
diagnosis of Alzheimer’s disease, who were significantly 
older at symptom onset (mean 66·4 years, SD 8·1) than 
individuals with other phenotypes (p<0·0001 for all 
comparisons). In the MAPT group, we found no significant 
differences in age at symptom onset between individuals 
with behavioural variant frontotemporal dementia and 
those with primary progressive aphasia; however, indi­
viduals with Alzheimer’s disease were significantly older 
at symptom onset (mean 56·7 years, SD 11·1) than 
those with behavioural variant frontotemporal dementia 
(p=0·0006), primary progress ive aphasia (p=0·013), and a 
combined corticobasal syndrome and progressive supra­
nuclear palsy (atypical parkinsonism; p<0·0001). Further­
more, individuals in the MAPT group with atypical 
parkinsonism were significantly younger at symptom 
onset (mean 44·9 years, SD 7·8) than those with other 
phenotypes (individuals with atypical parkinsonism vs 
those with behavioural variant frontotemporal dementia 
p=0·013; vs individuals with primary progressive aphasia 
p=0·037).
The mean age at death was lowest in individuals 
with MAPT mutations and highest in those with GRN 
mutations (p<0·0001 for all comparisons between groups; 
table 1). Age at death was variable within genetic groups 
(table 1, figure 2) and within individual mutations (app­
endix pp 6–10, 37). As with age at symptom onset, we 
found no significant differences in age at death between 
men and women in the MAPT group, but found sig­
nificant differences between men and women in the GRN 
group (mean 69·4 years, SD 10·2, in women vs 67·8 years, 
8·8, in men; p=0·029) and C9orf72 group (66·1 years, 
11·0, in women vs 64·6 years, 10·8, in men; p=0·034; 
appendix p 44).
As with age at symptom onset, individuals with a diag­
nosis of Alzheimer’s disease in all three genetic groups 
were significantly older at death than individuals with 
other phenotypes (appendix pp 45–46). In the C9orf72 
group, individuals with a diagnosis of amyotrophic lateral 
sclerosis were significantly younger (mean 59·2 years, 
SD 9·7) at death compared with those with a diagnosis 
of frontotemporal dementia with amyotrophic lateral 
scler osis (62·1 years, 8·9; p=0·014) and those with a 
diagnosis of behavioural variant frontotemporal dementia 
(64·6 years, 9·0; p<0·0001). In turn, individuals with a 
diag nosis of frontotemporal dementia with amyotrophic 
lateral sclerosis were younger at death than those with a 
diagnosis of behavioural variant fronto temporal dementia 
(p=0·014). In the MAPT group, individuals with a diag­
nosis of atypical parkinsonism were significantly younger 
at death (mean 52·8 years, SD 8·9) compared with those 
with a diagnosis of behavioural variant fronto temporal 
dementia (60·6 years, 9·9; p=0·030) and those with a 
diagnosis of primary progressive aphasia (60·9 years, 
15·2; p=0·036).
The mean disease duration was lowest for individuals 
with C9orf72 expansions, followed by those with GRN 
mutations, and those with MAPT mutations (p≤0·0005 for 
each comparison; table 1). However, within each genetic 
group, several individuals survived for many decades; the 
longest surviving individuals lived 27 years from symptom 
onset in the GRN group, 36 years in the C9orf72 group, 
and 45 years in the MAPT group (table 1, figure 2, 
appendix p 38). Although variability within individual 
mutations existed (appendix pp 6–10, 38), mean disease 
duration was similar across the GRN group, except for a 
significantly longer disease duration in individuals with 
an Ala9Asp mutation compared with those with Gly35fs, 
Thr272fs, and Arg493X mutations (appendix p 40). We 
found a greater variability in the mean disease duration in 
the MAPT group than in the GRN group. Individuals with 
an Arg406Trp mutation had a significantly longer disease 
duration than those with Pro301Leu and Asn279Lys 
mutations, and individuals with an IVS10+16C→T 
GRN
(n=1179)
MAPT
(n=791)
C9orf72
(n=1433)
Diagnoses within the frontotemporal dementia spectrum
Behavioural variant frontotemporal dementia 446 (37·8%) 354 (44·8%) 450 (31·4%)
Non-fluent variant primary progressive aphasia 107 (9·1%) 14 (1·8%) 26 (1·8%)
Semantic variant primary progressive aphasia 13 (1·1%) 14 (1·8%) 13 (0·9%)
Logopenic variant primary progressive aphasia 4 (0·3%) 0 (0%) 3 (0·2%)
Primary progressive aphasia not otherwise specified* 36 (3·1%) 2 (0·3%) 4 (0·3%)
Frontotemporal dementia with amyotrophic lateral sclerosis 7 (0·6%) 2 (0·3%) 157 (11·0%)
Amyotrophic lateral sclerosis 7 (0·6%) 1 (0·1%) 276 (19·3%)
Corticobasal syndrome 47 (4·0%) 14 (1·8%) 2 (0·1%)
Progressive supranuclear palsy† 0 (0%) 33 (4·2%) 1 (0·1%)
Diagnoses outside the frontotemporal dementia spectrum
Alzheimer’s disease 97 (8·2%) 24 (3·0%) 84 (5·9%)
Huntington’s disease 0 (0%) 1 (0·1%) 4 (0·3%)
Parkinson’s disease 16 (1·4%) 39 (4·9%) 15 (1·0%)
Dementia with Lewy Bodies 4 (0·3%) 1 (0·1%) 5 (0·3%)
Vascular dementia 9 (0·8%) 1 (0·1%) 7 (0·5%)
Dementia not otherwise specified* 361 (30·6%) 274 (34·6%) 362 (25·3%)
Other 25 (2·1%) 17 (2·1%) 24 (1·7%)
*Does not meet criteria for a specific subtype. †Richardson’s syndrome.
Table 2: Clinical diagnoses in each of the three genetic groups
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mutation had a significantly longer disease duration than 
those with Pro301Leu mutations (appendix pp 40, 47–48).
We found no significant differences in disease dura­
tion between men and women in any of the groups 
(appendix p 44). We observed no significant differences in 
disease duration between clinical phenotypes in the GRN 
and MAPT groups (appendix pp 45–46). However, indi­
viduals with C9orf72 expansions and a diag nosis of 
amyotrophic lateral sclerosis had a significantly lower 
disease duration (mean 2·9 years, SD 2·8) than those 
of the other groups (p<0·0001 for all comparisons); 
indi viduals with C9orf72 expansions and a diagnosis of 
fronto temporal dementia with amyotrophic lateral scler­
osis also had a lower disease duration (5·0 years, 4·2) 
than that of those with C9orf72 expansions and behavi oural 
variant frontotemporal dementia (7·8 years, 4·4; p<0·0001), 
primary progressive aphasia (7·5 years, 4·8; p=0·0016), 
and Alzheimer’s disease (10·4 years, 4·9; p<0·0001; 
appendix pp 45–46).
Individual age at symptom onset significantly correlated 
with both parental and mean family age at symptom onset 
in all three genetic groups (p<0·0001; figure 4); in each 
group, individual age at symptom onset either had a 
similar correlation with parental and mean family age or 
a stronger correlation with mean family age than with 
parental age. The strength of these correlations varied 
across the genetic groups, being strongest in the MAPT 
group and weakest in the GRN group (figure 4). As with 
age at symptom onset, individual age at death significantly 
correlated with both parental age at death and mean 
family age at death in all three genetic groups (p<0·0001). 
We observed a similar pattern to that of age at symptom 
onset in the three genetic groups: the MAPT group had 
the strongest correlation (r=0·69 for mean family age at 
death, r=0·58 for parental age at death), followed by the 
C9orf72 group (r=0·40, r=0·38) and the GRN group 
(r=0·32, r=0·22).
We found significant differences between the three 
mutation groups in the inter­family and intra­family 
variability of age at symptom onset (both p<0·0001; 
appendix p 49). Family membership explained 66% 
(95% CI 56–75) of this variability in individuals with 
MAPT mutations, but only 14% (9–22) in those with GRN 
mutations and 17% (11–26) in those with C9orf72 expan­
sions. We observed a significant difference between the 
GRN and MAPT groups in the between­mutation vari­
ability in age at symptom onset (p<0·0001): in the GRN 
group, only 2% (95% CI 0–10) of the variability was 
explained by the specific mutation, whereas in the MAPT 
group, 48% (35–62) of the variability was explained by the 
specific mutation.
Significant differences were also found between the 
three genetic groups in the variability of inter­family and 
intra­family age at death (both p<0·0001; appendix p 49). 
Family membership explained 74% (95% CI 65–82) of 
this variability in individuals with MAPT mutations, 
but only 20% (12–30) in those with GRN mutations and 
19% (12–29) in those with C9orf72 expansions. We also 
found a significant difference between the GRN and 
MAPT groups in the between­mutation variability in age 
at death (p<0·0001): in the GRN group, only 9% (95% CI 
3–21) of the variability was explained by the specific 
mutation, whereas in the MAPT group, 61% (47–73) of 
the variability was explained by the specific mutation.
Discussion
To our knowledge, we report in this study the largest 
dataset of age at onset, age at death, and disease duration 
in individuals with genetic frontotemporal dementia to 
date, incorporating data from across the world for the 
three main genetic groups and for all reported mutations 
in the GRN and MAPT groups. Our study provides 
evidence that an individual’s age at symptom onset and 
death in genetic frontotemporal dementia is modulated 
by both the individual mutation carried and family 
membership and varies by clinical phenotype and sex, 
with the strongest effect of these factors seen in indi­
viduals with MAPT mutations.
Our study provides further evidence that genetic 
frontotemporal dementia is a disorder that can occur 
throughout adult life, with symptom onset occurring from 
as early as the late teens to age 90 years or older. Although 
we did not account for individuals with mutations who 
were unaffected in the analysis, our findings are consistent 
with previous studies showing age­related penetrance in 
the GRN8 and C9orf72 9 groups, with individuals develop­
ing symptoms at age 90 years and older. A leftwards 
shift towards younger ages is evident in the penetrance 
curve in individuals with MAPT mutations (figure 3A) but 
Figure 2: Violin plots of age at symptom onset and at death for the three genetic groups
Data are median (bold lines) with IQR (dashed lines).
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nonetheless, the oldest age at symptom onset in this group 
was 82 years. Although usually considered a fully penetrant 
dis order, occasional incomplete penetrance might exist in 
some families with MAPT mutations (eg, Leu315Arg,10 
Val363Ile,11,12 and Gly389Arg13), which might be age­related.
The investigation of individual mutations within GRN 
revealed little difference between them in terms of age 
at symptom onset, age at death, or disease duration. These 
results are consistent with the underlying pathophysio­
logical mechanism of progranulin haplo­insufficiency 
being the same in most GRN mutations.14,15 By con­
trast, we found significant differences between individual 
MAPT mutations, with the mean symptom onset in 
the Asn279Lys mutation group occurring 12 years earlier 
than in the Arg406Trp mutation group. Along with the 
Val337Met mutation, the Arg406Trp mutation has a 
distinct pathological form compared with that of the other 
MAPT mutations, with the presence of tau pathology with 
paired helical filaments similar to that seen in Alzheimer’s 
disease; this group had a significantly longer disease 
duration than that of the other mutations, as previously 
described in single case reports.16
The generational analysis revealed significant differ­
ences in all three genetic groups, consistent with previous 
studies,4,17 with earlier age at symptom onset occurring in 
later (second) generations. These findings have been 
variably interpreted previously. One study has suggested 
that, in individuals with C9orf72 expansions, this finding 
was evidence of genetic anticipation.17 However, another 
research group interpreted this data as likely to be related 
to later generations recognising the disease earlier because 
of increased familiarity with symptoms and being more 
likely to be alert to the presence of such symptoms because 
of their awareness of being at­risk.4 At a molecular level, 
studies have shown that although C9orf72 expansions 
might be dynamic, they can both expand and contract 
across generations.17 Furthermore, no clear evidence exists 
for a relationship between age at symptom onset and 
expansion length, with contradictory evidence of both a 
positive correlation in some studies18–20 and an inverse 
correlation in another.21 Evidence against anticipation 
being an explanation for the earlier age at symptom onset 
in later generations also comes from the similar results 
observed in the GRN (corroborated by another study4) and 
MAPT groups: these mutations are stable and do not 
change molecularly across generations, therefore no 
plausible mechanism exists for anticipation in GRN or 
MAPT mutations.
Few studies have compared whether age at symptom 
onset, age at death, or disease duration vary by clinical 
phenotype within genetic groups. In our study, individuals 
with a diagnosis of Alzheimer’s disease within each group 
were significantly older at symptom onset than those 
with other diagnoses. Although it is possible that indivi­
duals with a true amnestic presentation of genetic fronto­
temporal dementia do present at an older age (and that an 
underlying biological explanation for this exists), this is 
more likely to be related to the misdiagnosis of individuals 
with late­onset dementia as having Alzheimer’s disease. In 
the MAPT group, individuals with an atypical parkinsonian 
syndrome were significantly younger at symptom onset 
and at death and had a shorter disease duration than those 
of the other groups—this was not entirely driven by the 
presence of a specific muta tion because the phenotype was 
Figure 3: Cumulative probability of symptom onset for each genetic 
group (A) and in the common GRN (B) and MAPT (C) mutations
Data includes only individuals who have become symptomatic and does not 
account for family members who are not symptomatic.
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seen across multiple mutations (eg, only 13% of this group 
had an Asn279Lys mutation, which has an earlier mean 
age at symptom onset than that of other mutations). In the 
C9orf72 group, the presence of amyotrophic lateral scler­
osis was associ ated with a shorter disease duration than 
that of other phenotypes (with amyotrophic lateral sclerosis 
alone having a significantly shorter disease duration than 
the combined phenotype of frontotemporal dementia with 
amyotrophic lateral sclerosis), as previously reported.22 A 
previous study compared a combined frontotemporal 
dementia group with an amyotrophic lateral sclerosis 
group in individuals with C9orf72 expansions and found 
an earlier onset in the amyotrophic lateral sclerosis group.9 
In our C9orf72 cohort, a significantly earlier onset was 
found in the amyotrophic lateral sclerosis group compared 
with that of a combined group of individuals with a 
cognitive presentation (appendix p 46), but this is partly 
driven by the Alzheimer’s disease group and no differ­
ences were found between the amyotrophic lateral sclerosis 
group and either the behavioural variant fronto temp­
oral dementia or primary progressive aphasia groups 
individually (appendix pp 45–46).
Individual age at symptom onset was significantly 
correlated with both parental age at symptom onset and 
mean family age at symptom onset in all three genetic 
groups. Similarly, individual age at death was significantly 
correlated with both parental age at death and mean family 
age at death in all three genetic groups. However, we found 
stronger correlations in the MAPT group than in the other 
two groups, similar to the results found in patients with 
familial Alzheimer’s disease.23 The variability in age at 
symptom onset and at death for individuals with MAPT 
mutations was partly explained by the specific mutation 
and more so by family mem bership. Unlike the other 
genetic groups, in the MAPT group, prediction of probable 
age at symptom onset and at death is therefore highly 
related to the presence of the MAPT mutation itself. Other 
genetic or environmental factors affecting age at symptom 
onset and at death in individuals with MAPT mutations 
have not yet been well studied.24
Despite being statistically significant, correlation 
coefficients were low in the GRN group for the com­
parisons between individual age at symptom onset and 
parental and mean family age at symptom onset. The 
variability in age at symptom onset and age at death for 
individuals with GRN mutations was not accounted for 
particularly by either the individual mutation or family 
membership. This finding is consistent with previous 
reports of large variability within families (and specific 
mutations), even within the same generation.25–27 Genetic 
factors affecting age at symptom onset include poly­
morphisms in TMEM106B28,29 and potentially also in 
PRNP,30 but several recent studies suggest that environ­
mental factors related to an altered neuro inflammatory 
response might also be important.31–34
The C9orf72 group sits between the GRN and MAPT 
groups in terms of the strength of correlation of individual 
age at symptom onset and at death with parental and 
mean family age at symptom onset and at death. However, 
similar to GRN mutations, the variability in age at symp­
tom onset and at death was not accounted for particularly 
by family membership. Although conflicting evidence 
exists about whether expansion length is relevant,18–21 
several studies have identified DNA methylation21,35,36 and 
a locus on chromosome 637 as important factors in age 
at symptom onset, age at death, and disease duration 
in individuals with C9orf72 expansions (see appendix 
for further discussion of potential modifiers of age at 
symptom onset and age at death [pp 49–50]).
Our study has several limitations. One such limitation 
was its focus on mainly retrospective data collection, with 
age at symptom onset recorded as the age at which an 
Figure 4: Correlation of individual age at symptom onset with parental (A) and mean familial (B) ages at 
symptom onset for GRN, MAPT, and C9orf72 genetic groups
Pearson’s correlation coefficient is shown on each graph. 
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individual was determined to have progressive cognitive, 
behavioural, or motor symptoms. As such, our data might 
be confounded by factors such as individual differences 
in interpreting symptom onset. This is a major issue in 
the study of frontotemporal dementia, for which objective 
measures of symptom onset are needed. A grey zone 
in proximity to symptom onset exists, in which subtle 
cognitive and behavioural deficits are present,7 but have 
not yet been identified as symptoms by the patient 
themselves or family members. Work within the FPI 
aims to identify such proximity markers, which will be 
important for future stratification in clinical trials, parti­
cularly, as identified in this study, for individuals with 
GRN and C9orf72 mutations, in whom prediction by age 
itself is poor.
Another limitation of the study is that we did not collect 
data on individuals with known muta tions who did not 
develop symptoms of frontotemporal dementia. This is 
particularly important when assessing age­related pene­
trance in the GRN and C9orf72 groups, although we did 
identify people older than 90 years developing symptoms 
of frontotemporal dementia in both these groups. Attain­
ment of data from long­living individuals with mutations 
will be important to better understand the modifiers of 
age at symptom onset and this will require large, well 
characterised longitudinal cohort studies, such as those in 
the FPI.
Although many of the centres in our study saw patients 
and families with all phenotypes of frontotemporal 
dementia, amyotrophic lateral sclerosis, and movement 
disorders within their clinics, the focus on genetic fronto­
temporal dementia within our study might have led to an 
underrepresentation of patients with amyotrophic lateral 
sclerosis or parkinsonian disorders. However, many of the 
families had members with multiple different phenotypes 
(including cognitive, behavioural, and motor), and few 
families had only a single phenotype, suggesting that the 
data in our study is unlikely to lead to a major discrepancy 
in phenotypic frequency.
Lastly, we did not have any data on the TMEM106B 
genotype (which is a known modifier in individuals with 
GRN mutations) nor on other genetic modifiers, such as 
APOE genotype, to further investigate their effect. How­
ever, such data, along with various environmental and 
lifestyle factors, are now being collected within the FPI 
and will be investigated in future studies.
In summary, we showed that individuals with MAPT 
mutations are younger at symptom onset and at death than 
those of the other groups, with the observed variance 
largely accounted for by family membership and the 
specific mutation carried. Indi viduals with GRN muta­
tions had the weakest association of age at symptom onset 
and at death with other family members, and most of the 
observed variance in age at symptom onset and at death 
was accounted for by neither family membership nor the 
specific mutation. However, we found a sex effect, with 
increased prevalence of symptomatic individuals and 
older age at onset in women than in men, probably 
driven by age­related penetrance seen in those with GRN 
mutations. C9orf72 expansions were the overall most 
common cause of genetic frontotemporal dementia in our 
study. Pheno typical differences in disease duration exist, 
with the presence of amyotrophic lateral sclerosis leading 
to a shortened disease duration. As in the GRN group, 
little of the variance in age at symptom onset or at death 
was accounted for by family membership, with other 
genetic and environmental factors likely to be involved.
Our study highlights the strength of collaborative studies 
in rare diseases, bringing together data from across the 
world to better understand genetic frontotemporal dem­
entia and to provide important data relevant to future trial 
designs. The prospective cohort studies within the FPI will 
hopefully provide solutions to some of the unanswered 
questions over the forthcoming years.
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